LYCA Stock Forecast: Lycia Therapeutics, Inc. Price Predictions for 2026-2027
Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 0 of 100 as at 31 Oct 2026 — in the weakest quartile.
LYCA stock analysis: one number for the whole business
Consensus tells you what everyone already believes. The model scores Lycia Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (39): Smaller than most of the companies we track.
Issuance (0): The company has been issuing shares or taking on financing, diluting existing holders.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
LYCA stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on LYCA, reported as data — targets and ratings, the market's view beside the model's.
We don’t hold enough price history for this company yet.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
This page is one stock. Monday covers all of them.
LYCA appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track, part by part, and one part in full with each verdict.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
LYCA analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Lycia Therapeutics, Inc. (LYCA) financial data
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- 310.1×
- Price / book
- —
- EV / EBITDA
- −16.5×
Cheaper than 2% of US stocks
Cheaper than 89% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- −762.3%
- Net margin
- 0.0%
Higher than 6% of US stocks
Higher than 30% of US stocks
- Return on equity
- —
- Return on assets
- —
- Dividend yield
- 0.0%
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
Lycia Therapeutics, Inc. (LYCA) statistics: revenue, profit & scale
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Lycia Therapeutics, Inc. has a market value of $1.4B and an enterprise value of $542.7M.
Forward dividend yield: 0.00%.
Lycia Therapeutics, Inc. employs 31 people.
Data provided by Twelve Data
LYCA vs competitors
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Lycia Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Frequently asked questions about LYCA stock
How does Ticker Nerd's model rank LYCA?
As at 31 Oct 2026, Lycia Therapeutics, Inc. ranks 0 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (39 of 100).
What is the LYCA stock forecast for 2030?
No analyst covering Lycia Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for LYCA are extrapolating price history, which says nothing about the business.
What does Lycia Therapeutics, Inc. do?
Lycia Therapeutics, Inc. is a clinical-stage biotechnology company developing medicines that remove disease-driving proteins from outside cells.
About Lycia Therapeutics, Inc.
Lycia Therapeutics, Inc. is a clinical-stage biotechnology company developing medicines that remove disease-driving proteins from outside cells. Its core technology, the lysosomal targeting chimera platform, is designed to direct soluble and membrane-bound extracellular proteins to lysosomes, the cell’s natural waste-processing compartments, for degradation. This approach supports the development of targeted protein degraders for conditions in oncology, immunology, inflammation, and other areas of significant unmet medical need. The company’s current pipeline includes cataLYTAC programs such as LCA-0061, focused on allergic disease, and LCA-0321, directed toward Graves’ disease. By addressing proteins that may be difficult to inhibit with conventional drug modalities, Lycia Therapeutics, Inc. operates at the intersection of protein biology, drug discovery, and precision medicine. Headquartered in South San Francisco, California, the company represents a specialized biotechnology business focused on translating extracellular protein degradation into potential therapeutic products.
CEO Dr. Aetna Wun Trombley Ph.D. · 31 employees · United States · https://lyciatx.com